Jean Hurteau

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 578 citations · Full text

Combination Cediranib, Medicine, Olaparib Versus Olaparib +9

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy

Loren K. Mell, J.D. Kochanski, John C. Roeske et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 328 citations

Acute Hematologic Toxicity, Cervical Cancer, Radiation Therapy +8

Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.

Yan Xu, Douglas C. Gaudette, Jessica Boynton et al. · PubMed · 1995 · 324 citations

Oncology, Chemoprevention Strategy, Biochemistry +14

Bleomycin, Etoposide, and Cisplatin Combination Therapy of Ovarian Granulosa Cell Tumors and Other Stromal Malignancies: A Gynecologic Oncology Group Study

Howard D. Homesley, Brian N. Bundy, Jean Hurteau et al. · Gynecologic Oncology · 1999 · 250 citations

Malignant Disease, Medicine, Gynecology +7

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

J.F. Liu, William T. Barry, Michael J. Birrer et al. · Annals of Oncology · 2019 · 181 citations · Full text